Determinants of bone specific metastasis in prostate cancer

https://doi.org/10.1016/j.critrevonc.2017.02.013Get rights and content

Abstract

Prostate cancer is one of the most common type of cancer in Western countries. Although the majority of patients with PCa have a minimally aggressive disease, some of them will experience relapse and formation of metastasis. Bone metastasis are a major cause of quality of life impairment and death among patients with metastatic prostate cancer. Different “bone targeted therapies” and several follow-up strategies were developed in order to optimize bone metastasis prevention and treatment. Nevertheless there is still a great clinical need of identifying patients more likely to benefit from those interventions as not all patients will develop metastatic disease and not all patients with metastatic disease will develop bone metastasis. Here we review markers predictive of bone metastasis occurrence that have been tested in clinical settings, particularly focusing on the ability of such markers to predict bone metastasis over visceral metastasis occurrence.

Introduction

As for any type of metastasis, bone-metastatic tumor cells retain specific properties that make them specifically fit only for the establishment of skeletal metastasis (Croucher et al., 2016). Although most patient with metastatic prostate cancer (PCa) will develop bone metastases, visceral metastasis occur in up to 15% of patients with PCa and, depending on the series, roughly 5% of PCa patients will develop only visceral metastasis (Gandaglia et al., 2015).

The metastatic process occurs through different steps (Massague and Obenauf, 2016). Each of these steps is potentially detectable and useful in a clinical setting. Prediction of bone metastasis might help change the clinical approach as for prevention and treatment is concerned. Patients at high risk for bone metastasis would likely benefit more from adjuvant androgen deprivation therapy or from bone targeted therapy to prevent or delay bone metastasis, and could be monitored proportionally to their clinical risk, allowing an optimization of disease follow up (Briganti et al., 2014).

The pathophysiology of bone metastasis formation is still far to be fully understood but is increasingly being elucidated by different experimental models and clinical evidences. Here we aim to review all those factors that demonstrated to predict bone metastasis occurrence in PCa patients.

Section snippets

CTCs and DTCs

The metastatic process, in order to occur, needs some cancerous cells from the primary tumor to acquire the capability of enter and survive in the systemic circulation. A minority of these circulating tumor cells (CTCs) can extravasate to other site and enter a quiescent status: these dormant cells are referred to as disseminated tumor cells (DTCs). Eventually these dormant cells can start proliferate and – even years after their establishment – form new metastasis (Massague and Obenauf, 2016).

Bone turnover markers

Bone turnover markers (BTMs) are biochemical products whose level in peripheral blood reflects the metabolism of the bone. Since any bone metastatic cancer determines changes in bone metabolism it has been postulated that BTMs might somehow be exploited in order to figure out bone metastasis presence and progression in different cancer subtypes. BTMs include markers of bone formation (P1NP, P1CP, bALP and OC) and markers of bone resorption (OP, NTX-I, CTX-I and BSP) (Ferreira et al., 2015) (

RANK/RANKL/OPG

It is well-established that the pathway of receptor activator of NF-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) is crucial for the formation of bone metastasis and this is particularly true for PCa (Chu and Chung, 2014). In a preclinical setting the activity of RANKL in PCa has shown to drive epithelial to mesenchymal transition (EMT) in vitro and to enhance aggressiveness of PCa cell lines in vivo (Odero-Marah et al., 2008); similarly in PCa cell lines exogenous RANKL was shown to

miRNAs

The relatively recent discovery of microRNAs (miRNAs) release by tumor cells led to great efforts in trying to define their possible clinical role in different settings (Endzelins et al., 2016).

Josson et al. found that cancer associated fibroblast could promote PCa cells EMT through a extracellular vescicle-mediated transfer of miR-409 and, in fact, cancer associated fibroblast from PCa patients have higher expression of miR-409 compared to healthy tissue fibroblast (Josson et al., 2015).

Exosomes

Tumor derived exosomes affect metastasis development in several ways (Zhang and Grizzle, 2014). Exosome can modify the metastatic niche prior to the arrival of tumor: when bone marrow coming from mice treated with exosome deriving from different melanoma cell lines was transplanted in a new mouse, the latter mouse was more prone to bone metastasis formation compared to a negative control mouse (Peinado et al., 2012). Single cells can modify the phenotype of withstanding cancerous and

Others

The analysis of genomic signature has been investigated in different settings. The Decipher score is a risk score obtained from the expression of 22 different genes linked to PCa aggressiveness; this score, calculated from surgical samples of patients with localized PCa underwent radical prostatectomy, is effective in predicting biochemical relapse, metastasis occurrence (Ross et al., 2016) and cancer specific mortality (Cooperberg et al., 2015). A higher Decipher score is correlated to a

Conclusions

The issue of bone metastasis prediction has been addressed by several authors. Although the identification of different types of markers, the clinical practice still relies on “classical” markers of PCa progression in order to predict bone metastasis recurrence (such as PSA, Gleason score and pTNM). We suggest that future studies conducted on bone targeted therapies should evaluate outcomes depending on baseline patients characteristics different from classical markers of disease relapse;

References (89)

  • E.A. Klein

    A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy

    Eur. Urol.

    (2015)
  • E.A. Klein

    Decipher genomic classifier measured on prostate biopsy predicts metastasis risk

    Urology

    (2016)
  • A.E. Ross

    Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men

    Eur. Urol.

    (2016)
  • O. Sartor

    Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

    Lancet Oncol.

    (2014)
  • M.R. Smith

    Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

    Lancet

    (2012)
  • H.G. Zhang et al.

    Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions

    Am. J. Pathol.

    (2014)
  • X.H. Zhang

    Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma

    Cell

    (2013)
  • A. Zomer

    In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior

    Cell

    (2015)
  • J. Akech

    Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions

    Oncogene

    (2010)
  • B.D. Angst et al.

    The cadherin superfamily: diversity in form and function

    J. Cell Sci.

    (2001)
  • E.S. Antonarakis

    AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

    N. Engl. J. Med.

    (2014)
  • A.P. Armstrong

    RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes

    Prostate

    (2008)
  • R.J. Bryant

    Changes in circulating microRNA levels associated with prostate cancer

    Br. J. Cancer

    (2012)
  • Q. Chen et al.

    The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review

    Drug Des. Dev. Ther.

    (2015)
  • G. Chen

    Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation

    Cancer

    (2006)
  • J.F. Chen

    Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases

    Cancer

    (2015)
  • W.Y. Chen

    MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer

    Oncotarget

    (2015)
  • G.C. Chu et al.

    RANK-mediated signaling network and cancer metastasis

    Cancer Metastasis Rev.

    (2014)
  • K. Chu

    Cadherin-11 promotes the metastasis of prostate cancer cells to bone

    Mol. Cancer Res.

    (2008)
  • M. Colombel

    Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases

    Prostate

    (2012)
  • D. Correa

    Mesenchymal stem cells regulate melanoma cancer cells extravasation to bone and liver at their perivascular niche

    Int. J. Cancer

    (2016)
  • P.I. Croucher et al.

    Bone metastasis: the importance of the neighbourhood

    Nat. Rev. Cancer

    (2016)
  • C. de la Piedra

    Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

    Br. J. Cancer

    (2013)
  • J. Dai

    Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms

    Cancer Res.

    (2008)
  • D.C. Danila

    Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer

    Clin. Cancer Res.

    (2007)
  • I.J. Diel

    Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis

    Clin. Cancer Res.

    (1999)
  • E. Endzelins

    Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review

    Mol. Cancer

    (2016)
  • A. Ferreira

    Bone remodeling markers and bone metastases: from cancer research to clinical implications

    Bonekey Rep.

    (2015)
  • A. Goldkorn

    Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer

    J. Clin. Oncol.

    (2014)
  • K. Gravdal

    A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer

    Clin. Cancer Res.

    (2007)
  • G. Gundem

    The evolutionary history of lethal metastatic prostate cancer

    Nature

    (2015)
  • M. Gururajan

    miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer

    Clin. Cancer Res.

    (2014)
  • C.L. Hall

    Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis

    Prostate

    (2008)
  • P. Hu

    Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study

    PLoS One

    (2013)
  • Cited by (19)

    • Suppression of cathepsin a inhibits growth, migration, and invasion by inhibiting the p38 MAPK signaling pathway in prostate cancer

      2020, Archives of Biochemistry and Biophysics
      Citation Excerpt :

      For this reason, hormone deprivation therapy is a cornerstone treatment for the management and suppression of prostate cancer. However, hormone deprivation therapy can eventually lead to the development of androgen-independent prostate cancer, which is resistant to chemical castration and has a stronger probability of metastasizing into the bones or the brain [4,5]. Therefore, the discovery of novel therapeutic target genes for prostate cancer is important, and for this, numerous studies are being conducted to determine biomarker genes that can effectively suppress prostate cancer at all stages [6].

    View all citing articles on Scopus
    View full text